ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 4
RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection
Experts discuss key factors influencing the decision between immunotherapy (IO)/IO and various IO/tyrosine kinase inhibitor (TKI) combinations in advanced renal cell carcinoma (RCC) treatment, including patient characteristics, risk stratification, PD-L1 status, and other clinical features, while also exploring the patient experience with IO-TKI regimens, strategies for managing adverse effects, and the approach to hepatotoxicity management.
Video Player is loading.
Video content above is prompted by the following:
- When you’re evaluating treatment options for your advanced RCC patients today, what key factors drive your decision between the IO/IO approach with ipilimumab/nivolumab vs the various IO/TKI combinations like pembrolizumab/lenvatinib, pembrolizumab/axitinib, nivolumab/cabozantinib, or avelumab/axitinib? How do you weigh patient characteristics, risk stratification, PD-L1 status, and other clinical features in this decision?
- Dr Barata asks Dr Beckermann:Briefly discuss your perspective on the patient experience for patients undergoing IO/TKI regimens and explore strategies for their mitigation and management.
- Comment on how patterns of hepatoxicity differ across trials and discuss your general approach to management.
Related Content:
